Drugs / arpraziquantel
last change Jul 2026 re-read 2 minutes ago

arpraziquantel

Small molecule

Developed for
opisthorchiasis · schistosomiasis
Investigated by
Merck KGaA, Darmstadt, Germany · Jennifer Keiser · Lao Tropical and Public Health Institute

Trials 3 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02271984 Oct → Dec 2014 Merck KGaA, Darmstadt, Germany Completed No outcome recorded
Phase 21 trial
Phase 2 NCT07262814 Jul → Oct 2026 expected opisthorchiasis Jennifer Keiser Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT03845140 Sep 2019 → Oct 2021 schistosomiasis Merck KGaA, Darmstadt, Germany Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as arpraziquantel “Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and...” PMID 36893784 Mar 2023
1

“ascending doses of arpraziquantel in children infected with Opisthorchis viverrini” NCT07262814

Known as (r)-(-)-praziquantel ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551
Known as Arprazicuantel ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551
Known as L-praziquantel “Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and...” PMID 36893784 Mar 2023
Known as L-pzq ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551
Known as MSC2499550A ClinicalTrials.gov intervention name — accepted as the source's own label NCT02271984
Modality Small molecule CHEMBL1235551
Route Oral “Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods.” NCT02271984